We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s drug pricing watchdog has recommended that the National Health Service reimburse Pfizer lung cancer drug Xalkori, while rejecting to refund Novartis’ breast cancer therapy Everolimus and Janssen’s non-Hodgkin’s lymphoma drug Imbruvica. Read More
Investment firms T. Rowe and Alleghany have filed a suit against Valeant and six executives over the company’s sales strategy that involved price gouging and acquisitions, claiming those tactics cost investors billions. Read More
The UK’s drug pricing watchdog has recommended that the National Health Service reimburse Pfizer lung cancer drug Xalkori, while recommending against refunds for Novartis’ breast cancer therapy Everolimus and Janssen’s non-Hodgkin’s lymphoma drug Imbruvica. Read More
Less than a day after finalizing its acquisition of Allergan’s generics division, Israeli drugmaker Teva Pharmaceutical disclosed plans to pick up the company’s distribution arm for $500 million. Read More
Almost a year after Bayer settled pay-for-delay allegations involving its antibiotic Cipro, Allergan and Sanofi units have struck deals to resolve lingering Cipro claims in ongoing class action litigation, agreeing to pony up $100 million. Read More
A federal judge has ordered AbbVie to release documents to the Federal Trade Commission related to its marketing of its testosterone treatment AndroGel. Read More
Chicago is firing back at drugmakers that dismissed the relevance of a high court ruling to the city’s False Claims Act suit against them over their promotion of opioids. Read More